查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1876005

脂质体阿霉素：全球市场份额和排名、总收入和需求预测（2025-2031年）

Liposomal Doxorubicin - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 108 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年全球脂质体阿霉素市场规模预计为 9.74 亿美元，预计到 2031 年将下降至 7.24 亿美元，在 2025 年至 2031 年的预测期内，复合年增长率为 -3.5%。

本报告对近期关税调整和国际对脂质体阿霉素采取的战略反制措施的跨境产业布局、资本配置模式、区域经济相互依存关係以及供应链重组进行了全面评估。

脂质体阿霉素是一种化疗药物，其主要成分阿霉素（葱环类抗生素）被包裹在脂质体（微小的球形脂质囊泡）中。这种脂质体製剂能够增强药物向肿瘤组织的递送，延长药物在血液中的循环时间，并降低心臟毒性和其他与传统阿霉素相关的全身性副作用。它可用于治疗多种癌症，包括卵巢癌、乳癌、多发性骨髓瘤和卡波西氏肉瘤，特别适用于对标准化疗副作用敏感的患者。

脂质体阿霉素市场的主要驱动因素是人们对更安全、更有效的癌症治疗方法的需求日益增长，这些方案需要在保持疗效的同时最大限度地降低全身毒性。传统阿霉素广泛应用于肿瘤治疗，但它会带来严重的副作用，尤其是剂量限制性心臟毒性。脂质体製剂透过将阿霉素包裹在脂质双层中来解决这一难题，从而实现药物靶向递送至肿瘤部位，同时减少对正常组织的暴露。这显着提高了药物的安全性和患者耐受性，尤其是在长期或合併化疗中。人口老化、生活方式改变和诊断能力的提高导致全球癌症负担日益加重，进而引发了对先进肿瘤治疗方案的激增，进一步推动了脂质体製剂的应用。此外，随着个人化医疗和标靶药物递送系统的日益普及，脂质体阿霉素因其与脂质体製剂技术的兼容性，正逐渐成为转移性乳癌、卵巢癌、多发性骨髓瘤和卡波西氏肉瘤等疾病的首选治疗方案。监管机构的核准以及支持其作为一线治疗和挽救治疗疗效的临床证据，也促进了其市场认知度和应用范围的不断扩大。

儘管脂质体阿霉素具有治疗优势，但其市场仍面临许多显着挑战。其中一个主要障碍是脂质体製剂高的研发和生产成本。为确保其稳定性、生物利用度和批间一致性，需要复杂的生产流程和严格的品管。因此，其价格远高于传统化疗，这可能会限制患者的用药，尤其是在中低收入国家和医疗预算紧张的地区。此外，部分市场非专利药脂质体阿霉素的上市加剧了价格压力和竞争，引发了人们对原厂药（如Doxil（欧洲名称：Kalix））市场份额和利润率的担忧。供应链问题和以往脂质体阿霉素的供不应求影响了患者的治疗依从性，并削弱了人们对产品供应的信心。此外，脂质体製剂的生物等效性和产品替代方面的监管复杂性也为非专利处方药的市场准入和核准带来了挑战。从临床角度来看，虽然脂质体阿霉素可以降低心臟毒性，但它也会引起其他不良反应，例如掌跖红斑感觉异常，这可能会影响患者的依从性。应对这些挑战需要製剂创新、经济高效的生产、监管协调以及对真实世界疗效数据的持续投入，以支持脂质体化疗药物的更广泛应用。

本报告旨在按地区/国家、类型和应用对全球脂质体阿霉素市场进行全面分析，重点关注总销售量、收入、价格、市场份额和主要企业的排名。

本报告以销售（千）和收入（百万美元）为单位，对脂质体阿霉素市场规模、估算和预测进行了呈现，基准年为2024年，并涵盖了2020年至2031年的历史数据和预测数据。报告采用定量和定性分析相结合的方法，帮助读者制定脂质体阿霉素的业务/成长策略，评估市场竞争，分析自身在当前市场中的地位，并做出明智的商业决策。

市场区隔

公司

  • Johnson & Johnson
  • Sun Pharmaceutical
  • CSPC
  • Kinyond
  • Teva
  • Fudan-Zhangjiang
  • Zydus Cadila
  • TTY Biopharma
  • Baxter International
  • Nippon Kayaku

按类型分類的细分市场

  • 5 ml
  • 10 ml
  • 25 ml

应用领域

  • 乳癌
  • 肝癌
  • 肾癌
  • 多发性骨髓瘤
  • 卵巢癌
  • 其他的

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Liposomal Doxorubicin was estimated to be worth US$ 974 million in 2024 and is forecast to a readjusted size of US$ 724 million by 2031 with a CAGR of -3.5% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Liposomal Doxorubicin cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Liposomal doxorubicin is a chemotherapeutic drug in which doxorubicin, a widely used anthracycline antibiotic for cancer treatment, is encapsulated within liposomes-tiny, spherical lipid-based vesicles. This liposomal formulation enhances the drug's delivery to tumor tissues, prolongs circulation time in the bloodstream, and reduces cardiotoxicity and other systemic side effects commonly associated with conventional doxorubicin. It is used to treat various cancers, including ovarian cancer, breast cancer, multiple myeloma, and Kaposi's sarcoma, particularly in patients who are sensitive to the adverse effects of standard chemotherapy.

A key driver of the liposomal doxorubicin market is the increasing demand for safer and more effective cancer therapies that minimize systemic toxicity while maintaining therapeutic efficacy. Traditional doxorubicin, though widely used in oncology, is associated with severe adverse effects, particularly dose-limiting cardiotoxicity. The liposomal formulation addresses this issue by encapsulating doxorubicin in lipid bilayers, enabling targeted delivery to tumor sites while reducing exposure to healthy tissues. This significantly enhances the drug's safety profile and patient tolerability, especially in long-term or combination chemotherapy regimens. The growing global burden of cancer-driven by aging populations, lifestyle changes, and better diagnostic capabilities-has led to a surge in demand for advanced oncologic treatments, further propelling the use of liposomal formulations. Additionally, the increasing adoption of personalized medicine and targeted drug delivery systems aligns well with liposomal drug technologies, positioning liposomal doxorubicin as a preferred choice in indications such as metastatic breast cancer, ovarian cancer, multiple myeloma, and Kaposi's sarcoma. Regulatory approvals and clinical evidence supporting its efficacy in both first-line and salvage therapy settings are also contributing to broader market acceptance and use.

Despite its therapeutic advantages, the liposomal doxorubicin market faces several notable challenges. One of the primary hurdles is the high cost of liposomal drug development and production, which involves complex manufacturing processes and strict quality controls to ensure stability, bioavailability, and batch consistency. This results in a significantly higher price point compared to conventional chemotherapy, which can limit accessibility-particularly in low- and middle-income countries or healthcare systems with constrained budgets. Moreover, the availability of generic liposomal doxorubicin products in some markets has led to pricing pressure and increased competition, raising concerns over market share and profit margins for originator brands like Doxil (Caelyx in Europe). Supply chain issues and past shortages of liposomal doxorubicin have also disrupted treatment continuity for patients and eroded confidence in product availability. Additionally, regulatory complexities related to bioequivalence and product substitution of liposomal formulations pose challenges for market entry and approval of generics. From a clinical perspective, while liposomal doxorubicin reduces cardiotoxicity, it may introduce other adverse effects such as palmar-plantar erythrodysesthesia (hand-foot syndrome), which can impact patient compliance. Addressing these challenges will require continued investment in formulation innovation, cost-effective manufacturing, regulatory harmonization, and real-world outcome data to support the broader adoption of liposomal chemotherapeutics.

This report aims to provide a comprehensive presentation of the global market for Liposomal Doxorubicin, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Liposomal Doxorubicin by region & country, by Type, and by Application.

The Liposomal Doxorubicin market size, estimations, and forecasts are provided in terms of sales volume (K Unit) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liposomal Doxorubicin.

Market Segmentation

By Company

  • Johnson & Johnson
  • Sun Pharmaceutical
  • CSPC
  • Kinyond
  • Teva
  • Fudan-Zhangjiang
  • Zydus Cadila
  • TTY Biopharma
  • Baxter International
  • Nippon Kayaku

Segment by Type

  • 5 ml
  • 10 ml
  • 25 ml

Segment by Application

  • Breast Cancer
  • Liver Cancer
  • Kidney Cancer
  • Multiple Myeloma
  • Ovarian Cancer
  • Other

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Liposomal Doxorubicin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Liposomal Doxorubicin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Liposomal Doxorubicin in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Liposomal Doxorubicin Product Introduction
  • 1.2 Global Liposomal Doxorubicin Market Size Forecast
    • 1.2.1 Global Liposomal Doxorubicin Sales Value (2020-2031)
    • 1.2.2 Global Liposomal Doxorubicin Sales Volume (2020-2031)
    • 1.2.3 Global Liposomal Doxorubicin Sales Price (2020-2031)
  • 1.3 Liposomal Doxorubicin Market Trends & Drivers
    • 1.3.1 Liposomal Doxorubicin Industry Trends
    • 1.3.2 Liposomal Doxorubicin Market Drivers & Opportunity
    • 1.3.3 Liposomal Doxorubicin Market Challenges
    • 1.3.4 Liposomal Doxorubicin Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Liposomal Doxorubicin Players Revenue Ranking (2024)
  • 2.2 Global Liposomal Doxorubicin Revenue by Company (2020-2025)
  • 2.3 Global Liposomal Doxorubicin Players Sales Volume Ranking (2024)
  • 2.4 Global Liposomal Doxorubicin Sales Volume by Company Players (2020-2025)
  • 2.5 Global Liposomal Doxorubicin Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Liposomal Doxorubicin Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Liposomal Doxorubicin Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Liposomal Doxorubicin
  • 2.9 Liposomal Doxorubicin Market Competitive Analysis
    • 2.9.1 Liposomal Doxorubicin Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Liposomal Doxorubicin Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Liposomal Doxorubicin as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 5 ml
    • 3.1.2 10 ml
    • 3.1.3 25 ml
  • 3.2 Global Liposomal Doxorubicin Sales Value by Type
    • 3.2.1 Global Liposomal Doxorubicin Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Liposomal Doxorubicin Sales Value, by Type (2020-2031)
    • 3.2.3 Global Liposomal Doxorubicin Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Liposomal Doxorubicin Sales Volume by Type
    • 3.3.1 Global Liposomal Doxorubicin Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Liposomal Doxorubicin Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Liposomal Doxorubicin Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Liposomal Doxorubicin Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Breast Cancer
    • 4.1.2 Liver Cancer
    • 4.1.3 Kidney Cancer
    • 4.1.4 Multiple Myeloma
    • 4.1.5 Ovarian Cancer
    • 4.1.6 Other
  • 4.2 Global Liposomal Doxorubicin Sales Value by Application
    • 4.2.1 Global Liposomal Doxorubicin Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Liposomal Doxorubicin Sales Value, by Application (2020-2031)
    • 4.2.3 Global Liposomal Doxorubicin Sales Value, by Application (%) (2020-2031)
  • 4.3 Global Liposomal Doxorubicin Sales Volume by Application
    • 4.3.1 Global Liposomal Doxorubicin Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global Liposomal Doxorubicin Sales Volume, by Application (2020-2031)
    • 4.3.3 Global Liposomal Doxorubicin Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global Liposomal Doxorubicin Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global Liposomal Doxorubicin Sales Value by Region
    • 5.1.1 Global Liposomal Doxorubicin Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Liposomal Doxorubicin Sales Value by Region (2020-2025)
    • 5.1.3 Global Liposomal Doxorubicin Sales Value by Region (2026-2031)
    • 5.1.4 Global Liposomal Doxorubicin Sales Value by Region (%), (2020-2031)
  • 5.2 Global Liposomal Doxorubicin Sales Volume by Region
    • 5.2.1 Global Liposomal Doxorubicin Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Liposomal Doxorubicin Sales Volume by Region (2020-2025)
    • 5.2.3 Global Liposomal Doxorubicin Sales Volume by Region (2026-2031)
    • 5.2.4 Global Liposomal Doxorubicin Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Liposomal Doxorubicin Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Liposomal Doxorubicin Sales Value, 2020-2031
    • 5.4.2 North America Liposomal Doxorubicin Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Liposomal Doxorubicin Sales Value, 2020-2031
    • 5.5.2 Europe Liposomal Doxorubicin Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Liposomal Doxorubicin Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Liposomal Doxorubicin Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Liposomal Doxorubicin Sales Value, 2020-2031
    • 5.7.2 South America Liposomal Doxorubicin Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Liposomal Doxorubicin Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Liposomal Doxorubicin Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Liposomal Doxorubicin Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Liposomal Doxorubicin Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Liposomal Doxorubicin Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Liposomal Doxorubicin Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Liposomal Doxorubicin Sales Value, 2020-2031
    • 6.3.2 United States Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Liposomal Doxorubicin Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Liposomal Doxorubicin Sales Value, 2020-2031
    • 6.4.2 Europe Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Liposomal Doxorubicin Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Liposomal Doxorubicin Sales Value, 2020-2031
    • 6.5.2 China Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Liposomal Doxorubicin Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Liposomal Doxorubicin Sales Value, 2020-2031
    • 6.6.2 Japan Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Liposomal Doxorubicin Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Liposomal Doxorubicin Sales Value, 2020-2031
    • 6.7.2 South Korea Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Liposomal Doxorubicin Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Liposomal Doxorubicin Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Liposomal Doxorubicin Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Liposomal Doxorubicin Sales Value, 2020-2031
    • 6.9.2 India Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Liposomal Doxorubicin Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Johnson & Johnson
    • 7.1.1 Johnson & Johnson Company Information
    • 7.1.2 Johnson & Johnson Introduction and Business Overview
    • 7.1.3 Johnson & Johnson Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 Johnson & Johnson Liposomal Doxorubicin Product Offerings
    • 7.1.5 Johnson & Johnson Recent Development
  • 7.2 Sun Pharmaceutical
    • 7.2.1 Sun Pharmaceutical Company Information
    • 7.2.2 Sun Pharmaceutical Introduction and Business Overview
    • 7.2.3 Sun Pharmaceutical Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 Sun Pharmaceutical Liposomal Doxorubicin Product Offerings
    • 7.2.5 Sun Pharmaceutical Recent Development
  • 7.3 CSPC
    • 7.3.1 CSPC Company Information
    • 7.3.2 CSPC Introduction and Business Overview
    • 7.3.3 CSPC Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 CSPC Liposomal Doxorubicin Product Offerings
    • 7.3.5 CSPC Recent Development
  • 7.4 Kinyond
    • 7.4.1 Kinyond Company Information
    • 7.4.2 Kinyond Introduction and Business Overview
    • 7.4.3 Kinyond Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 Kinyond Liposomal Doxorubicin Product Offerings
    • 7.4.5 Kinyond Recent Development
  • 7.5 Teva
    • 7.5.1 Teva Company Information
    • 7.5.2 Teva Introduction and Business Overview
    • 7.5.3 Teva Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 Teva Liposomal Doxorubicin Product Offerings
    • 7.5.5 Teva Recent Development
  • 7.6 Fudan-Zhangjiang
    • 7.6.1 Fudan-Zhangjiang Company Information
    • 7.6.2 Fudan-Zhangjiang Introduction and Business Overview
    • 7.6.3 Fudan-Zhangjiang Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 Fudan-Zhangjiang Liposomal Doxorubicin Product Offerings
    • 7.6.5 Fudan-Zhangjiang Recent Development
  • 7.7 Zydus Cadila
    • 7.7.1 Zydus Cadila Company Information
    • 7.7.2 Zydus Cadila Introduction and Business Overview
    • 7.7.3 Zydus Cadila Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 Zydus Cadila Liposomal Doxorubicin Product Offerings
    • 7.7.5 Zydus Cadila Recent Development
  • 7.8 TTY Biopharma
    • 7.8.1 TTY Biopharma Company Information
    • 7.8.2 TTY Biopharma Introduction and Business Overview
    • 7.8.3 TTY Biopharma Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.8.4 TTY Biopharma Liposomal Doxorubicin Product Offerings
    • 7.8.5 TTY Biopharma Recent Development
  • 7.9 Baxter International
    • 7.9.1 Baxter International Company Information
    • 7.9.2 Baxter International Introduction and Business Overview
    • 7.9.3 Baxter International Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.9.4 Baxter International Liposomal Doxorubicin Product Offerings
    • 7.9.5 Baxter International Recent Development
  • 7.10 Nippon Kayaku
    • 7.10.1 Nippon Kayaku Company Information
    • 7.10.2 Nippon Kayaku Introduction and Business Overview
    • 7.10.3 Nippon Kayaku Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.10.4 Nippon Kayaku Liposomal Doxorubicin Product Offerings
    • 7.10.5 Nippon Kayaku Recent Development

8 Industry Chain Analysis

  • 8.1 Liposomal Doxorubicin Industrial Chain
  • 8.2 Liposomal Doxorubicin Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Liposomal Doxorubicin Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Liposomal Doxorubicin Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Liposomal Doxorubicin Market Trends
  • Table 2. Liposomal Doxorubicin Market Drivers & Opportunity
  • Table 3. Liposomal Doxorubicin Market Challenges
  • Table 4. Liposomal Doxorubicin Market Restraints
  • Table 5. Global Liposomal Doxorubicin Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Liposomal Doxorubicin Revenue Market Share by Company (2020-2025)
  • Table 7. Global Liposomal Doxorubicin Sales Volume by Company (2020-2025) & (K Unit)
  • Table 8. Global Liposomal Doxorubicin Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Liposomal Doxorubicin Price by Company (2020-2025) & (USD/Unit)
  • Table 10. Key Manufacturers Liposomal Doxorubicin Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Liposomal Doxorubicin Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Liposomal Doxorubicin
  • Table 13. Global Liposomal Doxorubicin Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Liposomal Doxorubicin as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Liposomal Doxorubicin Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Liposomal Doxorubicin Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Liposomal Doxorubicin Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Liposomal Doxorubicin Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Liposomal Doxorubicin Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Liposomal Doxorubicin Sales Volume by Type: 2020 VS 2024 VS 2031 (K Unit)
  • Table 22. Global Liposomal Doxorubicin Sales Volume by Type (2020-2025) & (K Unit)
  • Table 23. Global Liposomal Doxorubicin Sales Volume by Type (2026-2031) & (K Unit)
  • Table 24. Global Liposomal Doxorubicin Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Liposomal Doxorubicin Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Liposomal Doxorubicin Price by Type (2020-2025) & (USD/Unit)
  • Table 27. Global Liposomal Doxorubicin Price by Type (2026-2031) & (USD/Unit)
  • Table 28. Global Liposomal Doxorubicin Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Liposomal Doxorubicin Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global Liposomal Doxorubicin Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global Liposomal Doxorubicin Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global Liposomal Doxorubicin Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global Liposomal Doxorubicin Sales Volume by Application: 2020 VS 2024 VS 2031 (K Unit)
  • Table 34. Global Liposomal Doxorubicin Sales Volume by Application (2020-2025) & (K Unit)
  • Table 35. Global Liposomal Doxorubicin Sales Volume by Application (2026-2031) & (K Unit)
  • Table 36. Global Liposomal Doxorubicin Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global Liposomal Doxorubicin Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global Liposomal Doxorubicin Price by Application (2020-2025) & (USD/Unit)
  • Table 39. Global Liposomal Doxorubicin Price by Application (2026-2031) & (USD/Unit)
  • Table 40. Global Liposomal Doxorubicin Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global Liposomal Doxorubicin Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global Liposomal Doxorubicin Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global Liposomal Doxorubicin Sales Value by Region (2020-2025) & (%)
  • Table 44. Global Liposomal Doxorubicin Sales Value by Region (2026-2031) & (%)
  • Table 45. Global Liposomal Doxorubicin Sales Volume by Region (K Unit): 2020 VS 2024 VS 2031
  • Table 46. Global Liposomal Doxorubicin Sales Volume by Region (2020-2025) & (K Unit)
  • Table 47. Global Liposomal Doxorubicin Sales Volume by Region (2026-2031) & (K Unit)
  • Table 48. Global Liposomal Doxorubicin Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global Liposomal Doxorubicin Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global Liposomal Doxorubicin Average Price by Region (2020-2025) & (USD/Unit)
  • Table 51. Global Liposomal Doxorubicin Average Price by Region (2026-2031) & (USD/Unit)
  • Table 52. Key Countries/Regions Liposomal Doxorubicin Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions Liposomal Doxorubicin Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions Liposomal Doxorubicin Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions Liposomal Doxorubicin Sales Volume, (2020-2025) & (K Unit)
  • Table 56. Key Countries/Regions Liposomal Doxorubicin Sales Volume, (2026-2031) & (K Unit)
  • Table 57. Johnson & Johnson Company Information
  • Table 58. Johnson & Johnson Introduction and Business Overview
  • Table 59. Johnson & Johnson Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 60. Johnson & Johnson Liposomal Doxorubicin Product Offerings
  • Table 61. Johnson & Johnson Recent Development
  • Table 62. Sun Pharmaceutical Company Information
  • Table 63. Sun Pharmaceutical Introduction and Business Overview
  • Table 64. Sun Pharmaceutical Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 65. Sun Pharmaceutical Liposomal Doxorubicin Product Offerings
  • Table 66. Sun Pharmaceutical Recent Development
  • Table 67. CSPC Company Information
  • Table 68. CSPC Introduction and Business Overview
  • Table 69. CSPC Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 70. CSPC Liposomal Doxorubicin Product Offerings
  • Table 71. CSPC Recent Development
  • Table 72. Kinyond Company Information
  • Table 73. Kinyond Introduction and Business Overview
  • Table 74. Kinyond Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 75. Kinyond Liposomal Doxorubicin Product Offerings
  • Table 76. Kinyond Recent Development
  • Table 77. Teva Company Information
  • Table 78. Teva Introduction and Business Overview
  • Table 79. Teva Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 80. Teva Liposomal Doxorubicin Product Offerings
  • Table 81. Teva Recent Development
  • Table 82. Fudan-Zhangjiang Company Information
  • Table 83. Fudan-Zhangjiang Introduction and Business Overview
  • Table 84. Fudan-Zhangjiang Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 85. Fudan-Zhangjiang Liposomal Doxorubicin Product Offerings
  • Table 86. Fudan-Zhangjiang Recent Development
  • Table 87. Zydus Cadila Company Information
  • Table 88. Zydus Cadila Introduction and Business Overview
  • Table 89. Zydus Cadila Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 90. Zydus Cadila Liposomal Doxorubicin Product Offerings
  • Table 91. Zydus Cadila Recent Development
  • Table 92. TTY Biopharma Company Information
  • Table 93. TTY Biopharma Introduction and Business Overview
  • Table 94. TTY Biopharma Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 95. TTY Biopharma Liposomal Doxorubicin Product Offerings
  • Table 96. TTY Biopharma Recent Development
  • Table 97. Baxter International Company Information
  • Table 98. Baxter International Introduction and Business Overview
  • Table 99. Baxter International Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 100. Baxter International Liposomal Doxorubicin Product Offerings
  • Table 101. Baxter International Recent Development
  • Table 102. Nippon Kayaku Company Information
  • Table 103. Nippon Kayaku Introduction and Business Overview
  • Table 104. Nippon Kayaku Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 105. Nippon Kayaku Liposomal Doxorubicin Product Offerings
  • Table 106. Nippon Kayaku Recent Development
  • Table 107. Key Raw Materials Lists
  • Table 108. Raw Materials Key Suppliers Lists
  • Table 109. Liposomal Doxorubicin Downstream Customers
  • Table 110. Liposomal Doxorubicin Distributors List
  • Table 111. Research Programs/Design for This Report
  • Table 112. Key Data Information from Secondary Sources
  • Table 113. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Liposomal Doxorubicin Product Picture
  • Figure 2. Global Liposomal Doxorubicin Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Liposomal Doxorubicin Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Liposomal Doxorubicin Sales Volume (2020-2031) & (K Unit)
  • Figure 5. Global Liposomal Doxorubicin Sales Price (2020-2031) & (USD/Unit)
  • Figure 6. Liposomal Doxorubicin Report Years Considered
  • Figure 7. Global Liposomal Doxorubicin Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Liposomal Doxorubicin Players Sales Volume Ranking (2024) & (K Unit)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Liposomal Doxorubicin Revenue in 2024
  • Figure 10. Liposomal Doxorubicin Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. 5 ml Picture
  • Figure 12. 10 ml Picture
  • Figure 13. 25 ml Picture
  • Figure 14. Global Liposomal Doxorubicin Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 15. Global Liposomal Doxorubicin Sales Value Market Share by Type, 2024 & 2031
  • Figure 16. Global Liposomal Doxorubicin Sales Volume by Type (2020 VS 2024 VS 2031) & (K Unit)
  • Figure 17. Global Liposomal Doxorubicin Sales Volume Market Share by Type, 2024 & 2031
  • Figure 18. Global Liposomal Doxorubicin Price by Type (2020-2031) & (USD/Unit)
  • Figure 19. Product Picture of Breast Cancer
  • Figure 20. Product Picture of Liver Cancer
  • Figure 21. Product Picture of Kidney Cancer
  • Figure 22. Product Picture of Multiple Myeloma
  • Figure 23. Product Picture of Ovarian Cancer
  • Figure 24. Product Picture of Other
  • Figure 25. Global Liposomal Doxorubicin Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 26. Global Liposomal Doxorubicin Sales Value Market Share by Application, 2024 & 2031
  • Figure 27. Global Liposomal Doxorubicin Sales Volume by Application (2020 VS 2024 VS 2031) & (K Unit)
  • Figure 28. Global Liposomal Doxorubicin Sales Volume Market Share by Application, 2024 & 2031
  • Figure 29. Global Liposomal Doxorubicin Price by Application (2020-2031) & (USD/Unit)
  • Figure 30. North America Liposomal Doxorubicin Sales Value (2020-2031) & (US$ Million)
  • Figure 31. North America Liposomal Doxorubicin Sales Value by Country (%), 2024 VS 2031
  • Figure 32. Europe Liposomal Doxorubicin Sales Value, (2020-2031) & (US$ Million)
  • Figure 33. Europe Liposomal Doxorubicin Sales Value by Country (%), 2024 VS 2031
  • Figure 34. Asia Pacific Liposomal Doxorubicin Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. Asia Pacific Liposomal Doxorubicin Sales Value by Region (%), 2024 VS 2031
  • Figure 36. South America Liposomal Doxorubicin Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. South America Liposomal Doxorubicin Sales Value by Country (%), 2024 VS 2031
  • Figure 38. Middle East & Africa Liposomal Doxorubicin Sales Value, (2020-2031) & (US$ Million)
  • Figure 39. Middle East & Africa Liposomal Doxorubicin Sales Value by Country (%), 2024 VS 2031
  • Figure 40. Key Countries/Regions Liposomal Doxorubicin Sales Value (%), (2020-2031)
  • Figure 41. Key Countries/Regions Liposomal Doxorubicin Sales Volume (%), (2020-2031)
  • Figure 42. United States Liposomal Doxorubicin Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. United States Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
  • Figure 44. United States Liposomal Doxorubicin Sales Value by Application (%), 2024 VS 2031
  • Figure 45. Europe Liposomal Doxorubicin Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. Europe Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
  • Figure 47. Europe Liposomal Doxorubicin Sales Value by Application (%), 2024 VS 2031
  • Figure 48. China Liposomal Doxorubicin Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. China Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
  • Figure 50. China Liposomal Doxorubicin Sales Value by Application (%), 2024 VS 2031
  • Figure 51. Japan Liposomal Doxorubicin Sales Value, (2020-2031) & (US$ Million)
  • Figure 52. Japan Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
  • Figure 53. Japan Liposomal Doxorubicin Sales Value by Application (%), 2024 VS 2031
  • Figure 54. South Korea Liposomal Doxorubicin Sales Value, (2020-2031) & (US$ Million)
  • Figure 55. South Korea Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
  • Figure 56. South Korea Liposomal Doxorubicin Sales Value by Application (%), 2024 VS 2031
  • Figure 57. Southeast Asia Liposomal Doxorubicin Sales Value, (2020-2031) & (US$ Million)
  • Figure 58. Southeast Asia Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
  • Figure 59. Southeast Asia Liposomal Doxorubicin Sales Value by Application (%), 2024 VS 2031
  • Figure 60. India Liposomal Doxorubicin Sales Value, (2020-2031) & (US$ Million)
  • Figure 61. India Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
  • Figure 62. India Liposomal Doxorubicin Sales Value by Application (%), 2024 VS 2031
  • Figure 63. Liposomal Doxorubicin Industrial Chain
  • Figure 64. Liposomal Doxorubicin Manufacturing Cost Structure
  • Figure 65. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 66. Bottom-up and Top-down Approaches for This Report
  • Figure 67. Data Triangulation
  • Figure 68. Key Executives Interviewed